Marshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total value of $753,725.00. Following the sale, the chief executive officer now owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, December 11th, Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.94, for a total value of $821,450.00.
• On Wednesday, October 23rd, Marshall Fordyce sold 19,375 shares of Vera Therapeutics stock. The stock was sold at an average price of $40.39, for a total transaction of $782,556.25.
• On Wednesday, October 9th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $38.24, for a total transaction of $597,500.00.
• On Wednesday, September 25th, Marshall Fordyce sold 23,125 shares of Vera Therapeutics stock. The stock was sold at an average price of $46.05, for a total transaction of $1,064,906.25.

Vera Therapeutics Stock Performance

Shares of VERA opened at $42.60 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 1 year low of $14.20 and a 1 year high of $51.61. The firm has a fifty day moving average of $45.27 and a 200-day moving average of $40.49. The company has a market cap of $2.70 billion, a price-to-earnings ratio of -16.32 and a beta of 1.08.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). As a group, equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on VERA. Evercore ISI upgraded Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Guggenheim lifted their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. Scotiabank began coverage on Vera Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target on the stock. Wedbush lifted their price objective on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Finally, Wells Fargo & Company assumed coverage on shares of Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $59.22.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lord Abbett & CO. LLC grew its stake in shares of Vera Therapeutics by 41.1% in the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock worth $18,830,000 after purchasing an additional 124,197 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Vera Therapeutics by 2.1% in the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock worth $44,415,000 after purchasing an additional 20,223 shares during the period. Barclays PLC grew its position in Vera Therapeutics by 94.1% in the 3rd quarter. Barclays PLC now owns 85,395 shares of the company’s stock valued at $3,774,000 after buying an additional 41,394 shares in the last quarter. Y Intercept Hong Kong Ltd increased its stake in Vera Therapeutics by 283.1% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 30,911 shares of the company’s stock valued at $1,366,000 after buying an additional 22,843 shares during the period. Finally, Pier Capital LLC bought a new stake in shares of Vera Therapeutics during the 3rd quarter worth about $4,573,000. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.